WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025. The findings, highlighted across five posters, underscored significant advancements in achieving functional cures for chronic hepatitis B (cHBV) patients and the promising safety profile of Arbutus' emerging treatment options.